Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
Completed · Phase 2
Conditions studied: Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
In brief
RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well ixabepilone works in treating patients with metastatic germ cell tumors that are refractory to cisplatin.
Key facts
- Study ID
- NCT00070096
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 29
- Starts
- 2003-08-01
- Expected to finish
- 2007-06-01
- Last updated by the study team
- 2013-06-24
Who can join
Age: 16 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.